BACKGROUND: Outcomes for patients in the second-line setting of advanced urothelial carcinoma (UC) are dismal. The recognized prognostic factors in this context are Eastern Cooperative Oncology Group (ECOG) performance status (PS) >0, hemoglobin level (Hb) <10 g/dl, and liver metastasis (LM). OBJECTIVES: The purpose of this retrospective study of prospective trials was to investigate the prognostic value of time from prior chemotherapy (TFPC) independent of known prognostic factors. DESIGN, SETTING, AND PARTICIPANTS: Data from patients from seven prospective trials with available baseline TFPC, Hb, PS, and LM values were used for retrospective analysis (n=570). External validation was conducted in a second-line phase 3 trial comparing best supportive care (BSC) versus vinflunine plus BSC (n=352). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cox proportional hazards regression was used to evaluate the association of factors, with overall survival (OS) and progression-free survival (PFS) being the respective primary and secondary outcome measures. RESULTS AND LIMITATIONS: ECOG-PS >0, LM, Hb <10 g/dl, and shorter TFPC were significant prognostic factors for OS and PFS on multivariable analysis. Patients with zero, one, two, and three to four factors demonstrated median OS of 12.2, 6.7, 5.1, and 3.0 mo, respectively (concordance statistic=0.638). Setting of prior chemotherapy (metastatic disease vs perioperative) and prior platinum agent (cisplatin or carboplatin) were not prognostic factors. External validation demonstrated a significant association of TFPC with PFS on univariable and most multivariable analyses, and with OS on univariable analyses. Limitations of retrospective analyses are applicable. CONCLUSIONS: Shorter TFPC enhances prognostic classification independent of ECOG-PS >0, Hb <10 g/dl, and LM in the setting of second-line therapy for advanced UC. These data may facilitate drug development and interpretation of trials.
BACKGROUND: Outcomes for patients in the second-line setting of advanced urothelial carcinoma (UC) are dismal. The recognized prognostic factors in this context are Eastern Cooperative Oncology Group (ECOG) performance status (PS) >0, hemoglobin level (Hb) <10 g/dl, and liver metastasis (LM). OBJECTIVES: The purpose of this retrospective study of prospective trials was to investigate the prognostic value of time from prior chemotherapy (TFPC) independent of known prognostic factors. DESIGN, SETTING, AND PARTICIPANTS: Data from patients from seven prospective trials with available baseline TFPC, Hb, PS, and LM values were used for retrospective analysis (n=570). External validation was conducted in a second-line phase 3 trial comparing best supportive care (BSC) versus vinflunine plus BSC (n=352). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cox proportional hazards regression was used to evaluate the association of factors, with overall survival (OS) and progression-free survival (PFS) being the respective primary and secondary outcome measures. RESULTS AND LIMITATIONS: ECOG-PS >0, LM, Hb <10 g/dl, and shorter TFPC were significant prognostic factors for OS and PFS on multivariable analysis. Patients with zero, one, two, and three to four factors demonstrated median OS of 12.2, 6.7, 5.1, and 3.0 mo, respectively (concordance statistic=0.638). Setting of prior chemotherapy (metastatic disease vs perioperative) and prior platinum agent (cisplatin or carboplatin) were not prognostic factors. External validation demonstrated a significant association of TFPC with PFS on univariable and most multivariable analyses, and with OS on univariable analyses. Limitations of retrospective analyses are applicable. CONCLUSIONS: Shorter TFPC enhances prognostic classification independent of ECOG-PS >0, Hb <10 g/dl, and LM in the setting of second-line therapy for advanced UC. These data may facilitate drug development and interpretation of trials.
Authors: Guru Sonpavde; Cora N Sternberg; Jonathan E Rosenberg; Noah M Hahn; Matthew D Galsky; Nicholas J Vogelzang Journal: Lancet Oncol Date: 2010-05-25 Impact factor: 41.316
Authors: Guru Sonpavde; Jonathan E Rosenberg; Noah M Hahn; Matthew D Galsky; Rick Bangs; Cora N Sternberg; Nicholas J Vogelzang Journal: J Clin Oncol Date: 2010-02-16 Impact factor: 44.544
Authors: Matthew D Galsky; Svetlana Mironov; Alexia Iasonos; Joseph Scattergood; Mary G Boyle; Dean F Bajorin Journal: Invest New Drugs Date: 2006-12-05 Impact factor: 3.850
Authors: Michael Rink; Daniel J Lee; Matthew Kent; Evanguelos Xylinas; Hans-Martin Fritsche; Marko Babjuk; Antonin Brisuda; Jens Hansen; David A Green; Atiqullah Aziz; Eugene K Cha; Giacomo Novara; Felix K Chun; Yair Lotan; Patrick J Bastian; Derya Tilki; Paolo Gontero; Armin Pycha; Jack Baniel; Roy Mano; Vincenzo Ficarra; Quoc-Dien Trinh; Scott T Tagawa; Pierre I Karakiewicz; Douglas S Scherr; Daniel D Sjoberg; Shahrokh F Shariat Journal: BJU Int Date: 2012-09-03 Impact factor: 5.588
Authors: Joaquim Bellmunt; Toni K Choueiri; Ronan Fougeray; Fabio A B Schutz; Yacine Salhi; Eric Winquist; Stéphane Culine; Hans von der Maase; David J Vaughn; Jonathan E Rosenberg Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: Daniel P Petrylak; Catherine M Tangen; Peter J Van Veldhuizen; J Wendall Goodwin; Przemyslaw W Twardowski; James N Atkins; Shaker R Kakhil; Marianne K Lange; Mahesh Mansukhani; E David Crawford Journal: BJU Int Date: 2009-11-02 Impact factor: 5.588
Authors: David J Vaughn; Sandy Srinivas; Walter M Stadler; Roberto Pili; Daniel Petrylak; Cora N Sternberg; David C Smith; Sarah Ringuette; Edwin de Wit; Virginie Pautret; Claude George Journal: Cancer Date: 2009-09-15 Impact factor: 6.860
Authors: Tomasz M Beer; Bryan Goldman; Craig R Nichols; Daniel P Petrylak; Manoj Agarwal; Christopher W Ryan; E David Crawford Journal: Clin Genitourin Cancer Date: 2008-03 Impact factor: 2.872
Authors: Guru Sonpavde; Juliane Manitz; Chen Gao; Darren Tayama; Constanze Kaiser; Daniel Hennessy; Doris Makari; Ashok Gupta; Shaad Essa Abdullah; Guenter Niegisch; Jonathan E Rosenberg; Dean F Bajorin; Petros Grivas; Andrea B Apolo; Robert Dreicer; Noah M Hahn; Matthew D Galsky; Andrea Necchi; Sandy Srinivas; Thomas Powles; Toni K Choueiri; Gregory R Pond Journal: J Urol Date: 2020-06-18 Impact factor: 7.450
Authors: Yu-Ning Wong; Elizabeth R Plimack; Samuel Litwin; David Vaughn; James Lee; Wei Song; Gary R Hudes Journal: J Clin Oncol Date: 2013-04-20 Impact factor: 44.544
Authors: Richard M Bambury; David J Benjamin; Joshua L Chaim; Emily C Zabor; John Sullivan; Ilana R Garcia-Grossman; Ashley M Regazzi; Irina Ostrovnaya; Aryln Apollo; Han Xiao; Martin H Voss; Gopa Iyer; Dean F Bajorin; Jonathan E Rosenberg Journal: Oncologist Date: 2015-04-06
Authors: Guru Sonpavde; Gregory R Pond; Jonathan E Rosenberg; Dean F Bajorin; Toni K Choueiri; Andrea Necchi; Giuseppe Di Lorenzo; Joaquim Bellmunt Journal: J Urol Date: 2015-08-17 Impact factor: 7.450
Authors: Joaquim Bellmunt; Ronald de Wit; David J Vaughn; Yves Fradet; Jae-Lyun Lee; Lawrence Fong; Nicholas J Vogelzang; Miguel A Climent; Daniel P Petrylak; Toni K Choueiri; Andrea Necchi; Winald Gerritsen; Howard Gurney; David I Quinn; Stéphane Culine; Cora N Sternberg; Yabing Mai; Christian H Poehlein; Rodolfo F Perini; Dean F Bajorin Journal: N Engl J Med Date: 2017-02-17 Impact factor: 91.245
Authors: Walter M Stadler; David J Vaughn; Guru Sonpavde; Nicholas J Vogelzang; Scott T Tagawa; Daniel P Petrylak; Peter Rosen; Chia-Chi Lin; John Mahoney; Sanjiv Modi; Peter Lee; Marc S Ernstoff; Wu-Chou Su; Alexander Spira; Korinna Pilz; Richard Vinisko; Charles Schloss; Holger Fritsch; Charles Zhao; Michael A Carducci Journal: Cancer Date: 2013-12-11 Impact factor: 6.860